ERBB2 and breast cancer: The approval of alpelisib, a selective PI3K-alpha inhibitor, for the treatment of patients with PIK3CA mutant HR + /HER2− advanced BC progressing on prior endocrine therapies7 brought to a renewed interest in PIK3CA as predictive marker in HR + /HER2− BC.